Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative UFT/UZEL + irinotecan chemoradiotherapy followed by FOLFOX or CAPOX and postoperative adjuvant chemotherapy in locally advanced lower rectal cancer
jRCTs031210660Recruiting
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of tegafur + uracil, irinotecan, FOLFOX and Capecitabine + oxaliplatin in rectal cancer. Started Jun 2022; status: recruiting.
02
Drugs
tegafur + uracilirinotecanFOLFOXCapecitabine + oxaliplatin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on jRCTs031210660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210660.